A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Renal InsufficiencyKidney Disease
Interventions
DRUG

Sativex

Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.

Sponsors
All Listed Sponsors
lead

GW Pharmaceuticals Ltd

INDUSTRY